NEW YORK CITY, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
39m
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback